Cathepsin S promotes the development of pulmonary arterial hypertension

Am J Physiol Lung Cell Mol Physiol. 2019 Jul 1;317(1):L1-L13. doi: 10.1152/ajplung.00530.2018. Epub 2019 Apr 24.

Abstract

Cysteine cathepsin proteases play critical roles in cardiovascular disease progression and are implicated in extracellular matrix (ECM) degradation. Patients with pulmonary arterial hypertension (PAH) exhibit increased elastase production by pulmonary arterial smooth muscle cells (PASMCs), which is related to the degradation of elastic fibers and pulmonary vascular remodeling. However, the mechanism by which cathepsins regulate the ECM and PASMC proliferation in PAH remains unclear. We hypothesized that cathepsin proteases in PASMCs promote the development of PAH. Here, we show overexpression of cathepsin S (Cat S) and degradation of elastic laminae in the lungs of patients with idiopathic PAH and in the PASMCs of monocrotaline-induced PAH model (MCT-PAH) rats. In addition, pulmonary hypertension can be treated in MCT-PAH rats by administering a selective Cat S inhibitor, Millipore-219393, which stimulates peroxisome proliferator-activated receptor-γ (PPARγ) to inhibit the expression of Cat S, thus suppressing the proliferation and migration of MCT-PAH PASMCs. We then reduced Cat S or PPARγ expression by using small interfering RNA in human PASMCs to demonstrate a mechanistic link between Cat S signaling and PPARγ protein, and the results suggest that PPARγ is upstream of Cat S signaling. In conclusion, the activity of Cat S in pulmonary vascular remodeling and degradation of elastin fibers through the disruption of PPARγ is pathophysiologically significant in PAH.

Keywords: cathepsin S; peroxisome proliferator-activated receptor-γ; pulmonary vascular changes; smooth muscle cell.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Animals
  • Antihypertensive Agents / pharmacology
  • Cathepsins / antagonists & inhibitors
  • Cathepsins / genetics*
  • Cathepsins / metabolism
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Disease Models, Animal
  • Female
  • Gene Expression Regulation
  • Humans
  • Male
  • Middle Aged
  • Monocrotaline / administration & dosage
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / metabolism*
  • Myocytes, Smooth Muscle / pathology
  • PPAR gamma / antagonists & inhibitors
  • PPAR gamma / genetics*
  • PPAR gamma / metabolism
  • Pancreatic Elastase / genetics
  • Pancreatic Elastase / metabolism
  • Primary Cell Culture
  • Protease Inhibitors / pharmacology
  • Pulmonary Arterial Hypertension / chemically induced
  • Pulmonary Arterial Hypertension / drug therapy
  • Pulmonary Arterial Hypertension / genetics*
  • Pulmonary Arterial Hypertension / pathology
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / metabolism*
  • Pulmonary Artery / pathology
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction

Substances

  • Antihypertensive Agents
  • PPAR gamma
  • PPARG protein, human
  • Protease Inhibitors
  • RNA, Small Interfering
  • Monocrotaline
  • Cathepsins
  • Pancreatic Elastase
  • cathepsin S